Unionman Technology Co Ltd
SSE:688609
Unionman Technology Co Ltd
SSE:688609
Price:
8.53
CNY
0.95%
Market Closed
Market Cap:
¥4.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Unionman Technology Co Ltd
SSE:688609
|
CN |
|
Fuji Electric Industry Co Ltd
TSE:6654
|
JP |
|
S
|
Starhedge SA
WSE:SHG
|
PL |
|
Corem Property Group AB
STO:CORE A
|
SE |
|
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
|
US |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
US |
|
W
|
Water Oasis Group Ltd
HKEX:1161
|
HK |
|
G
|
GFoot Co Ltd
TSE:2686
|
JP |
|
C
|
China Fordoo Holdings Ltd
HKEX:2399
|
CN |
Income Statement
Earnings Waterfall
Unionman Technology Co Ltd
Unionman Technology Co Ltd
Income Statement
Unionman Technology Co Ltd
Unionman Technology Co Ltd
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
37
|
47
|
41
|
23
|
22
|
11
|
15
|
37
|
39
|
41
|
41
|
40
|
41
|
0
|
|
| Revenue |
2 802
N/A
|
2 995
+7%
|
2 849
-5%
|
2 403
-16%
|
2 449
+2%
|
2 197
-10%
|
2 095
-5%
|
2 171
+4%
|
2 292
+6%
|
2 351
+3%
|
2 476
+5%
|
2 508
+1%
|
2 393
-5%
|
2 273
-5%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(2 235)
|
(2 377)
|
(2 252)
|
(1 927)
|
(1 983)
|
(1 827)
|
(1 808)
|
(1 949)
|
(2 049)
|
(2 120)
|
(2 220)
|
(2 238)
|
(2 170)
|
(2 066)
|
|
| Gross Profit |
567
N/A
|
618
+9%
|
596
-3%
|
475
-20%
|
467
-2%
|
370
-21%
|
287
-22%
|
222
-23%
|
243
+10%
|
231
-5%
|
256
+11%
|
270
+5%
|
223
-18%
|
207
-7%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(418)
|
(445)
|
(435)
|
(394)
|
(382)
|
(395)
|
(409)
|
(430)
|
(459)
|
(464)
|
(440)
|
(400)
|
(412)
|
(403)
|
|
| Selling, General & Administrative |
(267)
|
(287)
|
(264)
|
(253)
|
(236)
|
(233)
|
(249)
|
(270)
|
(282)
|
(281)
|
(270)
|
(240)
|
(244)
|
(251)
|
|
| Research & Development |
(154)
|
(160)
|
(165)
|
(158)
|
(167)
|
(165)
|
(171)
|
(150)
|
(169)
|
(173)
|
(171)
|
(156)
|
(172)
|
(166)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(18)
|
0
|
0
|
0
|
(24)
|
0
|
0
|
0
|
(31)
|
0
|
0
|
|
| Other Operating Expenses |
3
|
2
|
(6)
|
36
|
22
|
3
|
10
|
14
|
(8)
|
(10)
|
0
|
27
|
4
|
14
|
|
| Operating Income |
149
N/A
|
173
+16%
|
161
-7%
|
82
-49%
|
85
+4%
|
(25)
N/A
|
(122)
-398%
|
(207)
-70%
|
(216)
-4%
|
(233)
-8%
|
(184)
+21%
|
(130)
+29%
|
(189)
-45%
|
(196)
-4%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
(30)
|
(41)
|
(33)
|
(19)
|
(18)
|
(3)
|
(8)
|
(31)
|
(34)
|
(39)
|
(41)
|
(53)
|
(55)
|
(58)
|
|
| Non-Reccuring Items |
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(2)
|
0
|
(0)
|
|
| Total Other Income |
(1)
|
(1)
|
(4)
|
(4)
|
(5)
|
(4)
|
(3)
|
(8)
|
(6)
|
(7)
|
(6)
|
(2)
|
(6)
|
(4)
|
|
| Pre-Tax Income |
118
N/A
|
131
+11%
|
124
-5%
|
60
-52%
|
62
+3%
|
(32)
N/A
|
(133)
-319%
|
(247)
-85%
|
(256)
-4%
|
(279)
-9%
|
(230)
+17%
|
(187)
+19%
|
(250)
-34%
|
(259)
-3%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(14)
|
(14)
|
(12)
|
(2)
|
(3)
|
8
|
21
|
41
|
45
|
44
|
37
|
36
|
38
|
39
|
|
| Income from Continuing Operations |
104
|
117
|
112
|
57
|
59
|
(23)
|
(112)
|
(205)
|
(211)
|
(235)
|
(194)
|
(152)
|
(212)
|
(220)
|
|
| Income to Minority Interest |
2
|
2
|
2
|
3
|
3
|
4
|
5
|
6
|
8
|
9
|
10
|
10
|
9
|
9
|
|
| Net Income (Common) |
106
N/A
|
119
+12%
|
114
-4%
|
60
-47%
|
62
+3%
|
(19)
N/A
|
(108)
-458%
|
(199)
-85%
|
(203)
-2%
|
(225)
-11%
|
(184)
+18%
|
(142)
+23%
|
(203)
-43%
|
(211)
-4%
|
|
| EPS (Diluted) |
0.21
N/A
|
0.23
+10%
|
0.22
-4%
|
0.12
-45%
|
0.13
+8%
|
-0.04
N/A
|
-0.22
-450%
|
-0.4
-82%
|
-0.41
-2%
|
-0.45
-10%
|
-0.37
+18%
|
-0.29
+22%
|
-0.41
-41%
|
-0.43
-5%
|
|
Switch to:
Switch to:
See Also
Discover More
